The multi-specific V-H-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

Edwards, CJ; Sette, A; Cox, C; Di Fiore, B; Wyre, C; Sydoruk, D; Yadin, D; Hayes, P; Stelter, S; Bartlett, PD; Zuazo, M; Garcia-Granda, MJ; Benedetti, G; Fiaska, S; Birkett, NR; Teng, YM; Enever, C; Arasanz, H; Bocanegra, A; Chocarro, L; Fernandez, G; Vera, R; Archer, B; Osuch, I; Lewandowska, M; Surani, YM; Kochan, G; Escors, D; Legg, J; Pierce, AJ

Pierce, AJ (通讯作者)，Crescendo Biol Ltd, Meditrina Bldg,Babraham Res Campus, Cambridge CB22 3AT, England.

BRITISH JOURNAL OF CANCER, 2022; 126 (8): 1168

Abstract

Background Improving cancer immunotherapy long-term clinical benefit is a major priority. It has become apparent that multiple axes of immune suppress......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索